



Miltenyi Biotec

## Reference list

# CD133<sup>+</sup> stem cells in cardiovascular diseases

CliniMACS® CD133 Product line

## Contents

- A) Clinical
- B) Preclinical evaluation

### A) Clinical

#### **Autologous CD133<sup>+</sup> bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial<sup>†</sup>**

Nasseri BA, Ebell W, Dandel M, Kukucka M, Gebker R, Doltra A, Knosalla C, Choi Y-H, Hetzer R, Stamm C

European Heart Journal 2014 Feb.  
doi:10.1093/eurheartj/ehu007

#### **Analyzing migratory properties of human CD133 (+) stem cells in vivo after intraoperative sternal bone marrow isolation.**

Donndorf P, Useini D, Lux CA, Vollmar B, Delyagina E, Laupheimer M, Kaminski A, Steinhoff G.  
Cell Transplant 2013 Sept.; 22(9):1627-35

#### **Five-year follow-up of the local autologous transplantation of CD133<sup>+</sup> enriched bone marrow cells in patients with myocardial infarction.**

Ahmadi H, Farahani MM, Kouhkan A, Moazzami K, Fazeli R, Sadeghian H, Namiri M, Madani-Civi M, Baharvand H, Aghdami N.J  
Arch Iran Med. 2012 Jan;15(1):32-5.

#### **Impact of preoperative left ventricular function and time from infarction on the long-term benefits after intramyocardial CD133(+) bone marrow stem cell transplant.**

Yerebakan C, Kaminski A, Westphal B, Donndorf P, Glass A, Liebold A, Stamm C, Steinhoff G.  
J Thorac Cardiovasc Surg. 2011 Dec;142(6):1530-1539.e3. Epub 2011 Jun 12.

#### **Myocardial blood flow and infarct size after CD133<sup>+</sup> cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial.**

Colombo A, Castellani M, Piccaluga E, Pusineri E, Palatresi S, Longari V, Canzi C, Sacchi E, Rossi E, Rech R, Gerundini P, Viecca M, Delilieri GL, Rebulla P, Soligo D, Giordano R.

J Cardiovasc Med (Hagerstown). 2011 Apr; 12(4): 239-48.

#### **One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction.**

Mansour S, Roy DC, Bouchard V, Stevens LM, Gobeil F, Rivard A, Leclerc G, Reeves F, Noiseux N.  
Bone Marrow Res. 2011;2011:385124. Epub 2011 Feb 27.

#### **Safety and efficacy of bone marrow-derived autologous CD133<sup>+</sup> stem cell therapy.**

Adler DS, Lazarus H, Nair R, Goldberg JL, Greco NJ, Lassar T, Laughlin MJ, Das H, Pompili VJ.  
Front Biosci (Elite Ed). 2011 Jan 1;3: 506-14.

#### **Intracoronary infusion of selected autologous bone marrow stem cells improves longitudinal myocardial strain and strain rate in patients with old anterior myocardial infarction without recent revascularization.**

Karatasakis G, Leontiadis E, Peristeri I, Manginas A, Goussetis E, Graphakos S, Papadakis E, Cokkinos DV.  
Eur J Echocardiogr. 2010 Jun;11(5):440-5. Epub 2010 Mar 22.

**Intracoronary infusion of CD133+ endothelial progenitor cells improves heart function and quality of life in patients with chronic post-infarct heart insufficiency.**

*Flores-Ramírez R, Uribe-Longoria A, Rangel-Fuentes MM, Gutiérrez-Fajardo P, Salazar-Riojas R, Cervantes-García D, Treviño-Ortiz JH, Benavides-Chereti GJ, Espinosa-Oliveros LP, Limón-Rodríguez RH, Monreal-Puente R, González-Treviño JL, Rojas-Martínez A.* Cardiovasc RevascMed. 2010 Apr-Jun;11(2):72-8.

**Transmyocardial laser revascularization combined with intramyocardial endothelial progenitor cell transplantation in patients with intractable ischemic heart disease ineligible for conventional revascularization: preliminary results in a highly selected small patient cohort.**

*Babin-Ebell J, Sievers HH, Charitos EI, Klein HM, Jung F, Hellberg AK, Depping R, Sier HA, Marxsen J, Stoelting S, Kraatz EG, Wagner KF.* Thorac Cardiovasc Surg. 2010 Feb;58(1):11-6. Epub 2010 Jan 13.

**Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results.**

*Pompilio G, Steinhoff G, Liebold A, Pesce M, Alamanni F, Capogrossi MC, Biglioli P.* Thorac Cardiovasc Surg. 2008 Mar;56(2):71-6.

**Autologous bone marrow stem cell therapy for the ischemic myocardium during coronary artery bypass grafting.**

*Yerebakan C, Kaminski A, Westphal B, Liebold A, Steinhoff G.* MinimInvasiveTherAllied Technol.2008;17(2):143-8.

**Safety of intramyocardial stem cell therapy for the ischemic myocardium: results of the Rostock trial after 5-year follow-up.**

*Yerebakan C, Kaminski A, Liebold A, Steinhoff G.* Cell Transplant. 2007;16(9):935-40.

**Pilot study to evaluate the safety and feasibility of intracoronary CD133(+) and CD133(-) CD34(+) cell therapy in patients with nonviable anterior myocardial infarction.**

*Manginas A, Goussetis E, Koutelou M, Karatasakis G, Peristeri I, Theodorakos A, Leontiadis E, Plessas N, Theodosaki M, Graphakos S, Cokkinos DV.* Catheter Cardiovasc Interv. 2007 May 1; 69(6): 773-81.

**Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies.**

*Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold A, Nienaber C, Zurakowski D, Freund M, Steinhoff G.* J Thorac Cardiovasc Surg. 2007 Mar;133(3):717-25.

**Intramyocardial implantation of CD133+ stem cells improved cardiac function without bypass surgery.**

*Klein HM, Ghodsizad A, Marktanner R, Poll L, Voelkel T, Mohammad Hasani MR, Piechaczek C, Feifel N, Stocksclaeder M, Burchardt ER, Kar BJ, Gregoric I, Gams E.* Heart Surg Forum. 2007;10(1):E66-9.

**Intracoronary infusion of CD133+ and CD133- CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution.**

*Goussetis E, Manginas A, Koutelou M, Peristeri I, Theodosaki M, Kollaros N, Leontiadis E, Theodorakos A, Paterakis G, Karatasakis G, Cokkinos DV, Graphakos S.* Stem Cells. 2006 Oct;24(10):2279-83. Epub 2006 Jun 22.

**Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety.**

*Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, De Bondt P, Van Haute I, Lootens N, Heyndrickx G, Wijns W.* Circulation. 2005 Aug 30;112(9 Suppl):I178-83.

**Long-lasting improvement of myocardial perfusion and chronic refractory angina after autologous intramyocardial PBSC transplantation.**

*Pompilio G, Cannata A, Pesce M, Capogrossi MC, Biglioli P.* Cytotherapy. 2005;7(6):494-6.

**Autologous peripheral blood stem cell transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection.**

*Pompilio G, Cannata A, Peccatori F, Bertolini F, Nascimbene A, Capogrossi MC, Biglioli P.* Ann Thorac Surg. 2004 Nov;78(5):1808-12.

**Autologous bone marrow-derived stem cell therapy in combination with TMLR. A novel therapeutic option for endstage coronary heart disease: report on 2 cases.**

*Klein HM, Ghodsizad A, Borowski A, Saleh A, Draganov J, Poll L, Stoldt V, Feifel N, Piechaczek C, Burchardt ER, Stockscläder M, Gams E.* Heart Surg Forum. 2004;7(5):E416-9.

**Intraoperative isolation and processing of BM-derived stem cells.**

*Ghodsizad A, Klein HM, Borowski A, Stoldt V, Feifel N, Voelkel T, Piechaczek Ch, Burchardt E, Stockschläder M, Gams E.*  
Cytotherapy. 2004;6(5):523-6.

**CABG and bone marrow stem cell transplantation after myocardial infarction.**

*Stamm C, Kleine HD, Westphal B, Petzsch M, Kittner C, Nienaber CA, Freund M, Steinhoff G.*  
Thorac Cardiovasc Surg. 2004 Jun;52(3):152-8.

**Autologous bone-marrow stem-cell transplantation for myocardial regeneration.**

*Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schümichen C, Nienaber CA, Freund M, Steinhoff G.*  
Lancet. 2003 Jan 4;361(9351):45-6.

## **B) Preclinical evaluation**

**Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells.**

*Bissels U, Wild S, Tomiuk S, Hafner M, Scheel H, Mihailovic A, Choi YH, Tuschl T, Bosio A.*  
Stem Cells. 2011 May;29(5):847-57. doi: 10.1002/stem.627.

**Improved mobilization of the CD34(+) and CD133(+) bone marrow-derived circulating progenitor cells by freshly isolated intracoronary bone marrow cell transplantation in patients with ischemic heart disease.**

*Turan RG, Bozdog-Turan I, Ortak J, Akin I, Kische S, Schneider H, Turan CH, Rehders TC, Rauchhaus M, Kleinfeldt T, Adolph E, Brehm M, Yokus S, Steiner S, Sahin K, Nienaber CA, Ince H.*  
Stem Cells Dev. 2011 Sep;20(9):1491-501. Epub 2010 Dec 29.

**Autologous valve replacement-CD133+ stem cell-plus-fibrin composite-based sprayed cell seeding for intraoperative heart valve tissue engineering.**

*Kaminski A, Klopsch C, Mark P, Yerebakan C, Donndorf P, Gäbel R, Eisert F, Hasken S, Kreitz S, Glass A, Jockenhövel S, Ma N, Kundt G, Liebold A, Steinhoff G.*  
Tissue Eng Part C Methods. 2011 Mar;17(3):299-309. Epub 2010 Nov 22.

**Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood.**

*Koutna I, Peterkova M, Simara P, Stejskal S, Tesarova L, Kozubek M.*  
Ann Hematol. 2011 Feb;90(2):127-37. Epub 2010 Sep 4.

**Hypoxic/normoxic preconditioning increases endothelial differentiation potential of human bone marrow CD133+ cells.**

*Ong LL, Li W, Oldigs JK, Kaminski A, Gerstmayer B, Piechaczek C, Wagner W, Li RK, Ma N, Steinhoff G.*  
TissueEng Part C Methods. 2010 Oct;16(5):1069-81.

**Diabetes mellitus impairs CD133+ progenitor cell function after myocardial infarction.**

*Vöö S, Dunaeva M, Eggermann J, Stadler N, Waltenberger J.*  
J Intern Med. 2009 Feb;265(2):238-49. Epub 2008 Oct 25.

**Enhanced functional response of CD133+ circulating progenitor cells in patients early after acute myocardial infarction.**

*Vöö S, Eggermann J, Dunaeva M, Ramakers-van Oosterhoud C, Waltenberger J.*  
Eur Heart J. 2008 Jan;29(2):241-50. Epub 2007 Dec 20.

**Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure.**

*Schots R, De Keulenaer G, Schoors D, Caveliers V, Dujardin M, Verheye S, Van Camp G, Franken PR, Roland J, Van Riet I, Everaert H.*  
Exp Hematol. 2007 Dec;35(12):1884-90. Epub 2007 Oct 17.

**Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells.**

*Ma N, Ladilov Y, Moebius JM, Ong L, Piechaczek C, Dávid A, Kaminski A, Choi YH, Li W, Egger D, Stamm C, Steinhoff G.*  
Cardiovasc Res. 2006 Jul 1;71(1):158-69. Epub 2006 Apr 3.

Miltenyi Biotec provides products and services worldwide. Visit **[www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local)** to find your nearest Miltenyi Biotec contact.

The CliniMACS<sup>®</sup> System components: Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE).

CliniMACS<sup>®</sup> MicroBeads are for research use only and not for use in humans.

MACS and CliniMACS are registered trademarks or trademarks of Miltenyi Biotec GmbH. Copyright © 2014 Miltenyi Biotec GmbH. All rights reserved.